High-throughput single-cell-resolution genetic and pharmacological screens using

高通量单细胞分辨率遗传和药理学筛选

• 批准号: 8053299
• 负责人: Mehmet Fatih Yanik
• 金额: $ 31.64万
• 依托单位: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8053299
• 关键词: Cells; Development; Disease; Expenditure; Genetic; Neuraxis; Pattern; Pharmacologic Substance; Preclinical Drug Evaluation; Proteins; Resolution; Screening procedure; Stroke; Technology; Therapeutic; Trauma; combinatorial; high throughput screening; nervous system disorder; submicron; success; synaptogenesis

Despite the expenditure of billions of dollars on the development of new pharmaceuticals targeting the central nervous system (CNS), there are still no therapies against many devastating neurological disorders, diseases, stroke, and trauma. Limitations of existing high-throughput screening technologies have significantly hindered discovery of pharmaceuticals for the CNS. The CNS possesses a unique and dramatic complexity that requires a new paradigm in pharmaceutical screening. We propose a high- throughput screening technology that will permit most sophisticated single-cell resolution genetic and pharmacological screens by directing neuritogenesis and synaptogenesis at sub-micron resolution and on a large scale using combinatorial protein patterns.

尽管在针对中枢神经系统（CNS）的新药物开发的开发方面有数十亿美元的支出，但仍然没有针对许多毁灭性神经系统疾病，疾病，中风和创伤的疗法。现有的高通量筛查技术的局限性极大地阻碍了CNS的药物发现。中枢神经系统具有独特而戏剧性的复杂性，需要在药物筛查中采用新的范式。我们提出了一种高吞吐量筛查技术，该技术将通过使用组合蛋白质模式在次级微米分辨率和大规模上指导神经发生和突触发生，从而允许大多数复杂的单细胞遗传和药理学筛查。